Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature
European Journal of Clinical Microbiology & Infectious Diseases(2024)
摘要
Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2–7). Median time between two reinjections was 57 days (IQR 28–82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9
更多查看译文
关键词
Dalbavancin,Suppressive therapy,Prosthetic joint infection,Vascular graft infection,Dosage
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要